ArticleOcular immunology and inflammation2023
Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial.
Article in Ocular immunology and inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Efficacy of different routes of triamcinolone acetonide administration on macular edema: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- Custom-Made Injector for Suprachoroidal Ocular Delivery: Effect of Intraocular Pressure, Volume, and Location on the Distribution of Aqueous Solutions in Rabbits.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2025Article
- Pharmacotherapy for non-infectious uveitis: spotlight on phase III clinical trials of locally injected or implanted therapeutics and systemic immunomodulatory drugs.Journal of ophthalmic inflammation and infection · 2025Review
- Beyond the injection: delivery systems reshaping retinal disease management.Expert opinion on pharmacotherapy · 2025Review
- What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches.International ophthalmology · 2023Review
- Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies.Ophthalmology and therapy · 2023Article
- Review
- Photodynamic Therapy-Induced Acute Exudative Maculopathy (PAEM): Prevalence, Impact and Management Strategies.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema associated with uveitis.Expert review of ophthalmology · 2022Article
- Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis.Journal of vitreoretinal diseasesArticle
- Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTo study the efficacy and safety of suprachoroidal CLS-TA (proprietary suspension of triamcinolone acetonide) in uveitic macular edema (UME) with and without concurrent systemic corticosteroid or steroid-sparing therapy (ST).
methodsPost hoc analysis of the PEACHTREE phase 3 randomized trial.
resultsAmong UME patients receiving no ST, at week 24, mean BCVA change was +15.6 letters in 68 CLS-TA patients versus +4.9 letters in 49 sham-control patients (
conclusionsA clinically meaningful benefit of CLS-TA was noted in UME patients, regardless of concurrent ST usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.